GCV Israel 2018
Skip Content

13 March 2018

Xeris expands series C round to $85m

Mérieux Développement has helped to top up glucagon formulation developer Xeris Pharmaceuticals' series C round, alongside $45m in debt financing.

Author: Robert Lavine, News Editor

US-based drug formulation developer Xeris Pharmaceuticals has closed a series C round featuring Mérieux Développement, a subsidiary of healthcare and pharmaceutical holding company Institut Mérieux, at $85m.